The GeneSight Psychotropic test is a pharmacogenomic test that analyzes clinically important genetic variations which may impact how your patient metabolizes and responds to certain medications used to treat mental health conditions. The test is a powerful tool to augment your knowledge, experience and passion for your patients.
In a post-hoc analysis of data from the GUIDED study, the GeneSight Psychotropic test was found to significantly improve clinical outcomes in patients taking medications with gene-drug interactions compared to treatment as usual.1
Tens of thousands of clinicians have ordered the GeneSight test for 2 million patients and counting.
7 clinical studies published in peer-reviewed journals support the GeneSight test’s effectiveness. GeneSight Psychotropic is the only psychiatric pharmacogenomic test backed by such extensive research.
The GeneSight® Psychotropic report provides information about which medications may require dose adjustments, be less likely to work, or have an increased risk of side effects based on your patient’s genetic information.
The report categorizes medications into three color-coded categories and applies clinical considerations to explain the rationale for a medication’s classification. This information can be used to help inform treatment decisions.
Genotype/phenotype information is provided for 5 pharmacodynamic and 9 pharmacokinetic genes. COMT is also included for informational purposes.
The gene-drug interaction chart provides information on which pharmacokinetic genes are involved in the metabolism of each medication.
We will bill your patient’s insurance for the cost of the GeneSight test:
If your patient doesn’t have insurance, please contact our Customer Service team to find out how we can help.
We also offer a payment plan and a financial assistance program to help patients with their out of pocket cost. Learn more about these programs at GeneSight.com/cost
If you decide to use your insurance and we determine that your cost will exceed $330, we will contact you before processing the test and before billing you to make sure you would like to proceed.
All patients are eligible for the reduced Self-Pay option of $330. Self-Pay may be the most affordable option for patients whose out-of-pocket cost is estimated to be higher than $330, for those whose insurance does not cover the GeneSight test, or for those without insurance.
Fewer than 50% of patients with depression respond to their first prescribed medication and with each failed medication trial, their treatment intolerance increases.2
Consider offering the GeneSight test to:
The GeneSight test delivers genetic insights that may inform your treatment plan and potentially shorten your patients’ road to recovery.
To order the GeneSight test or request additional information, contact your sales representative or email [email protected]
Customer service [email protected] 866.757.9204
Medical information [email protected] 855.891.9415
Not all patients who receive the GeneSight test will have improved outcomes. The GeneSight test is intended to supplement a clinician’s comprehensive medical assessment.
*Based on a review of six months of past claim data for major insurance carriers across the US. Last updated 2023.